| 2021年1月29日 |
| 12:00 午後 - 01:30 午後 Eastern Standard Time |
| 11:00 午前 - 12:30 午後 Central Standard Time |
| 09:00 午前 - 10:30 午前 Pacific Standard Time |
In this session, FDA partners Kathleen Sanzo and Jacqueline Berman will explain how the biopharma industry is using AI to increase efficiencies during the drug development process, explore the legal and regulatory implications of AI’s application to clinical trials, and discuss the potential future of AI in the Food and Drug Administration’s drug and biologic divisions.